SCHEMBL5509709

SCHEMBL5509709

O=c1c2cc(F)ccc2nc2n1CCC2

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.70
KDM4E B2RXH2 4/20 0.70
SMN1; SMN2 Q16637 3/20 0.70
HSD17B10 Q99714 2/20 0.70
HPGD P15428 1/20 0.70
ACHE P22303 4/20 0.64
BCHE P06276 3/20 0.64
USP2 O75604 1/20 0.64
CYP1A2 P05177 1/20 0.64
CFTR P13569 1/20 0.64
ALOX15 P16050 1/20 0.64
HKDC1 Q2TB90 1/20 0.64
GOPC Q9HD26 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
APP P05067 3/20 0.64
RAB9A P51151 3/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5511724 0.96 ALDH1A1 (0.69) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL31563000 0.88 RAB9A (0.65) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL5507733 0.88 RAB9A (0.65) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL5506562 0.84 RAB9A (0.65) ALDH1A1KDM4ESMN1; SMN2HSD17B10ACHE
SCHEMBL5519389 0.82 ALDH1A1 (0.70) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL12457528 0.82 SMN1; SMN2 (1.00) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL17221319 0.82 ALDH1A1 (0.70) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL5505450 0.82 ALDH1A1 (0.61) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL11085523 0.81 ALDH1A1 (0.68) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL17221667 0.79 ALDH1A1 (0.65) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521583-B1 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO (2,1-B)-QUINAZOLINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2007-01-10 EP disclosed
US-7067519-B2 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2006-06-27 US disclosed
US-20050009852-A1 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates ACTELION PHARMACEUTICALS, LTD. (CH) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009852-A1 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates HCRTR2, HCRTR1, NPY1R ALDH1A1 1416/4885KDM4E 848/4885SMN1; SMN2 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.